Intellia Therapeutics, Inc. (NTLA) Institutional Ownership & Insider Trading

326 institutions reported holding Intellia Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 21 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NTLAIntellia Therapeutics, Inc.Follow NTLA — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.6B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

326 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +30.3%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	326	144	+30.3%	128	46	77	23
Mar 26	300	110	+10.6%	118	49	57	41
Dec 25	287	104	-0.2%	93	51	80	42
Sep 25	275	105	+4.6%	96	35	67	35
Jun 25	275	100	-2.5%	101	33	85	44
Mar 25	289	101	+2.1%	92	38	85	40
Dec 24	290	99	+2.4%	123	38	63	43
Sep 24	278	93	+0.9%	105	32	75	40

Intellia Therapeutics, Inc. — questions

Who owns Intellia Therapeutics, Inc. stock?: 326 institutions reported Intellia Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: ARK Investment Management LLC (12.0%), BlackRock, Inc. (11.0%), STATE STREET CORP (6.6%).
Are Intellia Therapeutics, Inc. insiders buying or selling?: 21 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Intellia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.